EyePoint Pharmaceuticals Q3 Earnings Snapshot
| IFRX Stock | USD 2.33 0.22 8.63% |
Slightly above 60% of InflaRx NV's investor base is looking to short. The analysis of the overall investor sentiment regarding InflaRx NV suggests that many traders are alarmed. InflaRx NV's investing sentiment can be driven by a variety of factors including economic data, InflaRx NV's earnings reports, geopolitical events, and overall market trends.
InflaRx |
WATERTOWN, Mass. AP EyePoint Pharmaceuticals on Thursday reported a loss of 29.4 million in its third quarter. On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 54 cents.
Read at finance.yahoo.com
 |
InflaRx NV Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards InflaRx NV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
InflaRx NV Fundamental Analysis
We analyze InflaRx NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InflaRx NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InflaRx NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
InflaRx NV is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
InflaRx NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InflaRx NV stock to make a market-neutral strategy. Peer analysis of InflaRx NV could also be used in its relative valuation, which is a method of valuing InflaRx NV by comparing valuation metrics with similar companies.
Peers
InflaRx NV Related Equities
| ERAS | Erasca | 3.00 | ||||
| PLX | Protalix Biotherapeutics | 1.34 | ||||
| EWTX | Edgewise Therapeutics | 0.08 | ||||
| CCCC | C4 Therapeutics | 0.52 | ||||
| IKNA | Ikena Oncology | 0.62 | ||||
| INZY | Inozyme Pharma | 0.71 | ||||
| KRON | Kronos Bio | 1.00 | ||||
| EYPT | Eyepoint Pharmaceuticals | 1.19 | ||||
| STOK | Stoke Therapeutics | 3.76 | ||||
| KZR | Kezar Life | 3.94 | ||||
| ELDN | Eledon Pharmaceuticals | 4.66 | ||||
| PASG | Passage Bio | 5.71 | ||||
| RVPH | Reviva Pharmaceuticals | 6.50 | ||||
| HOWL | Werewolf Therapeutics | 7.10 | ||||
| ABOS | Acumen Pharmaceuticals | 7.10 | ||||
| GLUE | Monte Rosa | 8.27 | ||||
| FULC | Fulcrum Therapeutics | 8.38 | ||||
| SLS | Sellas Life | 9.52 | ||||
| GBIO | Generation Bio | 12.50 | ||||
| DSGN | Design Therapeutics | 14.19 |
Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.